Omeros (NASDAQ:OMER) Share Price Passes Above Two Hundred Day Moving Average of $3.91

Omeros Co. (NASDAQ:OMER)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.91 and traded as high as $4.05. Omeros shares last traded at $4.00, with a volume of 250,940 shares trading hands.

Analysts Set New Price Targets

Several brokerages recently issued reports on OMER. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Friday, August 16th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Tuesday, June 4th.

Omeros Price Performance

The firm has a market cap of $231.80 million, a P/E ratio of -2.03 and a beta of 1.48. The firm has a fifty day simple moving average of $4.38 and a 200-day simple moving average of $3.91.

Omeros (NASDAQ:OMER) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter. On average, equities analysts predict that Omeros Co. will post -2.9 earnings per share for the current year.

Hedge Funds Weigh In On Omeros

A number of hedge funds have recently added to or reduced their stakes in OMER. Oppenheimer & Co. Inc. bought a new position in shares of Omeros in the first quarter valued at approximately $85,000. Coldstream Capital Management Inc. raised its position in Omeros by 42.1% in the 4th quarter. Coldstream Capital Management Inc. now owns 28,130 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 8,335 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Omeros by 75.5% during the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 12,951 shares in the last quarter. Comerica Bank boosted its holdings in Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 5,000 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Omeros in the 2nd quarter worth $105,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.